Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Publish Date : 12-Nov-2014

Solvay has opened a new facility to produce the synthetic building block ETFBO, expanding its range of fluorinated organic intermediates. The new €5 million facility has a capacity of 1,000 tonnes per year. Construction of the facility, integrated into an existing building, began in May this year and preliminary sample amounts were produced in October. “Solvay in Bad Wimpfen is our most important site for the production of these fluorinated specialty chemicals, and the only ETFBO supplier worldwide,” said Horst Kröger, Head of Strategic Marketing of Solvay’s Global Business Unit Special Chemicals. “Our local research know-how, qualified staff and many years of production experience are unique worldwide, giving us a competitive advantage. An additional benefit is that we are close to our key customers, manufacturers of agrochemicals.”

The so-called CF3 chemistry has been an important pillar for the site since the 1980s, when the production process for trifluoroacetyl chloride (TFAC) was developed. Today, it is a high revenue product, and a raw material for ETFBO. Additional CF3 products are rapidly entering our product range. ETFBO is a building block that boosts the efficiency of active ingredient molecules and makes them more easily biodegradable.

Large active ingredient molecules for pharmaceutical products and agrochemicals are put together from smaller, so-called synthetic building blocks. ETFBO (4-ethoxy-1,1,1-trifluoro-3-butene-2-one) is such a synthetic building block, which contributes both fluorine and a complex molecular structure to the active ingredient molecule at the same time. To begin with, only small amounts were synthesized for research purposes in Bad Wimpfen. These were then successfully tested in co-operation with selected customers. After that, ETFBO was produced at the industrial scale in a multi-purpose facility. The rapidly growing demand now makes a dedicated ETFBO facility viable.

Go to previous page